To validate LINC01198’s regulation of tumor immunity, we stably expressed two different sgRNAs targeting LINC01198’s TSS in MEL-526 and estrogen receptor-positive (ER+) breast cancer cell line MCF-7 (fig. This evidence concerns the gene ESR1 and breast carcinoma.